Virtual Library

Start Your Search

R. Komaki



Author of

  • +

    MTE06 - Radiotherapy Techniques in Lung Cancer (Ticketed Session) (ID 300)

    • Event: WCLC 2016
    • Type: Meet the Expert Session (Ticketed Session)
    • Track: Radiotherapy
    • Presentations: 1
    • Moderators:
    • Coordinates: 12/05/2016, 07:30 - 08:30, Strauss 3
    • +

      MTE06.01 - Radiotherapy Techniques in Lung Cancer (ID 6548)

      07:30 - 08:00  |  Author(s): R. Komaki

      • Abstract
      • Presentation
      • Slides

      Abstract:
      Recent Advances in Radiation Treatment Technique for Lung Cancer Lung cancer is the leading cause of cancer-related death in the United States and throughout the world. Advancement of Radiation Treatment have been parallel to imaging capability to target cancer and avoid surrounding normal tissue structure which associated with volume and dose. We can cure most of early lung cancer if it is well staged early cancer and targeted correctly by stereotactic body radiation therapy (SBRT). Because of high dose per fraction, technical aspects and quality assurance to deliver the radiation to the tumor precisely and avoid high dose of radiation to the critical surrounding normal tissue are critical issues organs in addition to controlling tumor motion. Technologic advancements of imaging and radiotherapy to conform the gross target volume(GTV) with tighter margins but adequate clinical targeted volume (CTV) and planning tumor volume (PTV) considering daily set up variations which are supposed to minimize the dose to nearby normal tissues. We have tried to answer higher radiation dose improve survival by the RTOG 0617 which compared overall survival after standard-dose versus high-dose intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiation therapy (3DCRT) with concurrent chemotherapy +/- cetuximab for patients with inoperable stage III non-small-cell lung cancer. In this open-label randomized, phase 3 study in 185 institutions in the USA and Canada, we enrolled patients (aged ≥18 years) with unresectable stage III non-small-cell lung cancer, a Zubrod performance status of 0–1, adequate pulmonary function, and no evidence of supraclavicular or contralateral hilar adenopathy. We randomly assigned (1:1:1:1) patients to receive either 60 Gy (standard dose), 74 Gy (high dose), 60 Gy plus cetuximab, or 74 Gy plus cetuximab. All received concurrent chemotherapy with 45 mg/m2 paclitaxel and carboplatin once a week (AUC 2); 2 weeks after chemoradiation, two cycles of consolidation chemotherapy separated by 3 weeks were given consisting of paclitaxel (200 mg/m2) and carboplatin (AUC 6). Radiation dose was prescribed to the PTV and was given in 2 Gy daily fractions with either IMRT or 3DCRT. For patients assigned to receive cetuximab, 400 mg/m2 cetuximab was given on day 1 followed by weekly doses of 250 mg/m2, and was continued through consolidation therapy. 166 patients were randomly assigned to receive standard-dose chemoradiotherapy, 121 to high-dose chemoradiotherapy, 147 to standard-dose chemoradiotherapy and cetuximab, and 110 to high-dose chemoradiotherapy and cetuximab. Median follow-up for the radiotherapy comparison was 22.9 months (IQR 27.5–33.3). Median overall survival was 28.7 months (95% CI 24.1–3.9) for patients who received standard-dose radiotherapy and 20.3 months (17.7–25.0) for those who received high-dose radiotherapy (hazard ratio [HR] 1.38, 95% CI 1.09–1.76; p=0.004). Median overall survival in patients who received cetuximab was 25.0 months (95% CI 20.2–30.5) compared with 24.0 months (19.8–28.6)in those who did not (HR 1.07, 95% CI 0.84–1.35; p=0.29). Both the radiation-dose and cetuximab results crossed protocol specified futility boundaries. We recorded no statistical differences in grade 3 or worse toxic effects between radiotherapy groups. By contrast, the use of cetuximab was associated with a higher rate of grade 3 or worse toxic effects (205 [86%] of 237 vs 160 [70%] of 228 patients; p<0.0001). There were more treatment-related deaths in the high-dose chemoradiotherapy and cetuximab groups (radiotherapy comparison: eight vs three patients; cetuximab comparison: ten vs five patients). Severe esophagitis was more common in patients who received high-dose chemoradiotherapy than in those who received standard-dose treatment (43 [21%] of 207 patients vs 16 [7%] of 217 patients; p<0.0001). This study did not mandate 4D simulation and possibly GTV was not well covered by the dose prescribed. There was higher local failure in the 74 Gy arm because of tighter margin in this group. We assumed from this study that 74 Gy radiation given in 2 Gy fractions with further improvements are expected from the use of charged particle therapy with protons or other particles; randomized comparisons of proton therapy vs. intensity-modulated photon radiation therapy for lung cancer are underway in the United States .A secondary analysis was performed to compare IMRT with 3D-CRT in NRG Oncology clinical trial RTOG 0617. The median follow-up was 21.3 months. Of 482 patients, 53% were treated with 3D-CRT and 47% with IMRT. The IMRT group had larger planning treatment volumes (median, 427 v 486 mL; P =.005); a larger planning treatment volume/volume of lung ratio (median, 0.13 v 0.15; P = .013); and more stage IIIB disease (30.3% v 38.6%, P = .056). Two-year OS, progression-free survival, local failure, and distance metastasis were not different between IMRT and 3D-CRT. IMRT was associated with fewer grade 3 or greater pneumonitis (7.9% v 3.5%, P = .039) and a reduced risk in adjusted analyses (odds ratio, 0.41; 95% CI, 0.171 to 0.986; P = .046). IMRT also produced lower heart doses (P <0 .05), and volume of heart receiving 40 Gy (V40) was significantly associated with OS on adjusted analysis (P<0.05). Lung V5 was not associated with any toxicity equal or greater than grade 3, whereas lung V20 was associated with increased grade 3 or greater pneumonitis risk on multivariable analysis (P = .026). IMRT was associated with lower rates of severe pneumonitis and cardiac doses in NRG Oncology clinical trial RTOG 0617, which supports routine use of IMRT for locally advanced NSCLC. We have evidence that severe pneumonitis and esophagitis have been reduced by proton compared to IMRT with concurrent chemotherapy for stage III NSCLC. However it is difficult to do a randomized trials. In conclusion, screening by low dose spiral CT scan for among previous or current smokers to detect early lung cancer. Early lung cancer can be curable by SBRT Lung cancer treatment planning requires 4D simulation. The technical advancement such as IMRT or Proton Treatment compared to 2 or 3 dimensional radiotherapy with concurrent chemotherapy reduced normal tissue toxicity among patients with locally advanced lung cancer which will improve their outcome in future. We are testing this hypothesis by a randomized prospective study.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.02 - Poster Session with Presenters Present (ID 462)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Locally Advanced NSCLC
    • Presentations: 1
    • +

      P2.02-037 - Final Results of Prospective Phase II Study of Adding Erlotinib to Chemoradiation for patients with Stage III Non-Small-Cell Lung Cancer (ID 5748)

      14:30 - 14:30  |  Author(s): R. Komaki

      • Abstract

      Background:
      Concurrent chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC) patients. We explored if adding erlotinib would increase the effectiveness of chemoradiotherapy, since we have demonstrated radiation sensitization by erlotinib in a preclinical setting using a mouse model.

      Methods:
      48 patients with stage III NSCLC, PS 0-1, received radiotherapy (63 Gy/35 fractions) on Monday‒Friday, with chemotherapy (paclitaxel 45 mg/m², carboplatin AUC=2) on Mondays, for 7 weeks. All patients also received EGFR-TKI erlotinib (150 mg orally 1/day) on Tuesday–Sunday for 7 weeks followed by consolidation paclitaxel–carboplatin. The primary endpoint was time to progression; secondary endpoints were overall survival (OS), toxicity, response, and disease control and whether any endpoint differed by EGFR mutation status.

      Results:
      46 out of 48 patients were evaluable for response; 40 were former or never smokers and 41 were evaluated for EGFR mutation status: 37 were wild-type and 4 were found to have mutation (3 exon 19 deletion, 1 exon 21 mutation). Median time to progression was 14 months and did not differ based on EGFR mutation status. Toxicity was acceptable: no grade 5 toxicity, I grade 4, and 11 grade 3). Twelve (26%) had complete responses (10 with wild type (wt) and 2 with mutation (mt) and 1 unknown). At 73.5 months median follow-up (range 46.2 - 93.7 months), 2 and 5 year OS rates were 67.4 % and 36.25%; there were no significant differences by mutation status. Twelve patients had no progression and 34 had local and/or distant metastasis. All 4 patients with EGFR mutation had local control. Eleven of 27 patients failed in the brain (7 wt, 3 mt and 1 unknown).

      Conclusion:
      Toxicity was acceptable and OS was promising, but time to progression did not meet expectations. The prevalence of distant failures underscores the need for effective systemic therapy. Those patients with EGFR mutation might need induction erlotinib followed by local treatment when they fail locally in the lung or brain which is fairly frequent among EGFR mutated patients.

  • +

    P2.05 - Poster Session with Presenters Present (ID 463)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Radiotherapy
    • Presentations: 1
    • +

      P2.05-015 - Long-Term Outcomes of Prospective Phase П Clinical Trial for Stereotactic Ablation Radiotherapy in Recurrent NSCLC (ID 5386)

      14:30 - 14:30  |  Author(s): R. Komaki

      • Abstract
      • Slides

      Background:
      To evaluate the long-term efficacy, pattern of failure, and toxicity of stereotactic ablative radiotherapy (SABR) for recurrent or multiple primary non-small-cell lung cancer (NSCLC).

      Methods:
      Patients with histologically confirmed, [18]F-fluorodeoxyglucose ([18]F-FDG)-PET staged, recurrent or multiple primary NSCLC, suitable for SABR (<5 cm, not abutting critical structures, met with SABR dose volume constraints),were prospectively enrolled and treated with volumetric image-guided SABR to 50 Gy in 4 fractions (prescribed to planning target volume). Lobar recurrent disease was defined as recurrence in the same lobe with the same histology after definitive therapy from prior NSCLC (n=9); recurrent or oligo-metastatic disease (<3 lesions) was defined as recurrence with same histology within four years in different lobe (n=35). Multiple primary NSCLC was defined as secondary NSCLC with either different histology, or same histology but located in the different lobe with more than 4 years after initial definitive treatment of prior NSCLC (n=16); synchronous tumors was defined as with two early stage NSCLC in the different side (n=3). Four-dimensional computed tomography (4DCT) was used for simulation and planning. Patients were followed with CT or PET/CT every three months for two years, then every 6 months for three years and then annually.

      Results:
      From February 2006 to April 2013, 63 patients were enrolled and eligible for evaluation. The median age was 70 years (range 45-86) and median follow-up was 4.2 years (the interquartile range 3.0-7.3 years). A total of 5 (7.9%) patients developed cumulative actual local recurrence within PTV and 18 patients (28.6%) developed any cumulative actual recurrence (local, regional and distant) after SABR. Estimated total local failure rates in the same lobe at 3-, 5-year were both 11.2% (95% CI 6.8-15.6). Estimated 3-, 5-year PFS rates were 60.2% (95% CI 53.7-66.7) and 52.6% (95% CI 43.5-61.7), respectively; corresponding overall survival rates were 64.1% (95% CI 58.0-70.2) and 52.9% (95% CI 45.5-60.3). Three (4.8%) patients developed grade 3 treatment-related adverse events (one [1.6%] dermatitis, one [1.6%] chest wall pain, and one [1.6%] radiation pneumonitis). No patient had grade 4 or 5 event.

      Conclusion:
      This exploratory prospective study showed excellent 5 years local control, minimal toxicity and outstanding 5 years OS and PFS for recurrent or multiple primary NSCLC treated with SABR, indicating a potential cure for some patients. Close follow up and surveillance after initial definitive treatment should be considered to detect early recurrence in NSCLC.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.